What The Experts Are Saying About Semaglutide (GLP-1 Agonist)

What It Is

Semaglutide mimics natural GLP-1 hormone for appetite control, blood sugar, and gastric slowing. FDA-approved: Ozempic (diabetes, up to 2 mg weekly, 2017), Wegovy (weight loss 2.4 mg weekly, 2021), oral Wegovy 25 mg daily (2025). Backed by massive STEP trials and SELECT outcomes data. Single-receptor (GLP-1 only) vs dual/triple like tirzepatide/retatrutide.

How It Works

• Brain: Suppresses appetite via hypothalamus POMC activation, reduces food reward/dopamine pull.
• Stomach: Delays emptying (37% meal retention at 4h vs 0% placebo), increases fullness.
• Pancreas: Boosts glucose-dependent insulin, suppresses glucagon—no hypo risk alone. Half-life ~7 days via albumin binding; weekly subQ or daily oral (low bioavailability).

Benefits

• Weight: 14.9–16% average loss (STEP trials); up to 20%+ with behavior support.
• Metabolic: Lowers glucose/HbA1c, improves insulin sensitivity.
• Cardio: 20% MACE reduction (SELECT, non-diabetics).
• Kidney: 24% risk drop (FLOW). Fat-focused loss with training/protein; lean mass preserved better long-term.

What to Expect

Titration 16–17 weeks to 2.4 mg weekly. Appetite drop week 1–2; peak loss months 3–9, plateaus ~15% at 1–2 years. No direct fat burn—creates calorie deficit via less hunger/intake. Stop: regain ~2/3 weight in 1 year without habits.

Side Effects & Risks

Common: Nausea (worst on titration), constipation, fatigue, sulfur burps.

Gallbladder risk up 37% (rapid loss). Thyroid C-cell tumors in rodents (boxed warning, rare human relevance). No suicide risk increase per FDA. Gastroparesis possible. Hold 1 week pre-surgery.

Comparisons

Tirzepatide: 20.2% vs 13.7% loss (SURMOUNT-5).

Retatrutide: ~28.7% (Phase 3), adds energy expenditure via glucagon.

Dosing & Tips

Standard weekly: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg.

Many succeed at lower doses. High protein (1g/lb goal BW) + resistance training 2–3x/week essential to minimize lean loss. Hydrate, small meals, fiber/magnesium for GI.

Stacking

• Resistance/protein: Best combo for muscle preservation.
• BPC-157/TB-500: OK, may ease GI.
• GH peptides/TRT: Compatible, supports composition. Avoid other GLP-1s.

Bottom Line

Powerful tool for deficit via appetite control. Maximizes results with training, protein, habits. Not magic—lifestyle locks in gains post-use. Research-grade available (e.g., Zesty Rat). Consult pros; not for MTC/MEN2 history.

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
2. Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413. https://pubmed.ncbi.nlm.nih.gov/33625476/
3. Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. https://pubmed.ncbi.nlm.nih.gov/36216945/
4. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
5. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/
6. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/
7. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
8. Wilding JPH, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. J Endocr Soc. 2021;5(Suppl 1):A16-A17. https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287/
9. Alissou M, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes Obes Metab. 2026;28(1):112-121. https://pubmed.ncbi.nlm.nih.gov/41068996/
10. Yang XD, Yang YY. Clinical Pharmacokinetics of Semaglutide: A Systematic Review. Drug Des Devel Ther. 2024;18:2555-2570. https://pmc.ncbi.nlm.nih.gov/articles/PMC11215664/
11. He L, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022;182(5):513-519. https://pubmed.ncbi.nlm.nih.gov/35344001/
12. Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. https://pubmed.ncbi.nlm.nih.gov/38785209/
13. Feier CVI, et al. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. Int J Mol Sci. 2024;25(8):4346. https://pmc.ncbi.nlm.nih.gov/articles/PMC11050669/

​